Oceanpine Merger Sub

Oceanpine Merger Sub was a special purpose acquisition vehicle and subsidiary of Oceanpine Capital, a private equity firm focused on global growth-stage investments. The entity was specifically established to facilitate the acquisition and take-private transaction of Anergi Therapeutics, a clinical-stage biopharmaceutical company. Following the completion of the merger in 2021, the entity was merged into the target company, with Anergi surviving as a private subsidiary of the Oceanpine-led consortium. The transaction was part of Oceanpine Capital's broader strategy to invest in high-potential healthcare and life science companies with significant cross-border growth opportunities.